Evidence map›Paper›PMID 27533720›Full record

ReviewPharmacogenomics2016

A review of consent practices and perspectives for pharmacogenetic testing.

Susanne B Haga, Rachel Mills

Abstract readReview
In one paragraph

Review in Pharmacogenomics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. How to Implement a Pharmacogenetics Service at your Institution.Journal of the American College of Clinical Pharmacy : JACCP · 2022
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Susanne B HagaCenter for Applied Genomics & Precision Medicine, Duke University, School of Medicine, 304 Research Drive, Box 90141, Durham, NC 27708, USA.
Rachel MillsCenter for Applied Genomics & Precision Medicine, Duke University, School of Medicine, 304 Research Drive, Box 90141, Durham, NC 27708, USA.

Funding

Pharmacogenetic Testing: Challenges of Clinical IntegrationR01GM081416 · NIGMS · DUKE UNIVERSITY · PI HAGA, SUSANNE · 2008 to 2018
$4.6M
NIGMS NIH HHS R01 GM081416
6 · The paper itself

Abstract

aimWe aimed to understand consent practices for pharmacogenetic (PGx) testing.

methodsWe conducted a literature review and analysis of consent forms from clinical laboratories offering PGx testing.

resultsOur review of the literature shows a lack of consensus about the need for and type of informed consent for PGx testing. We identified 35 companies offering PGx testing and were able to confirm consent practices for 22 of those. We found a range of variability in the consent practices regarding the consent approach and information disclosed.

conclusionVariability in the consent practices among laboratories offering PGx testing mirrors the ambiguous practices and recommendations reported in the literature. Establishing a minimal set of information to be disclosed to patients may help address the disparities in consent practice.

Indexed as

Informed ConsentPharmacogenomic TestingHumanscommunicationconsentpharmacogeneticspharmacogenetic testing

Identifiers

PMID27533720
PMCPMC5220438

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.